Associated Papers
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S1
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors.
Wu SG et al.
Erj Open Research, 2017
A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes.
Heideman DA et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology, 2009
EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.
Yokoyama T et al.
Cancer Science, 2006
Select a paper to view details